- Conditions
- Myelodysplastic Syndromes
- Interventions
- DEC-C, MyeloSeq-HD
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 6,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Relaxation Program, Questionnaires, Saliva Testing
- Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 45
- States / cities
- Mesa, Arizona • Fresno, California • Greenbrae, California + 39 more
- Conditions
- Lung Cancer, Tobacco Use
- Interventions
- Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation, Lay Navigator delivered outreach, shared decision-making, tobacco treatment, and navigation, Enhanced Usual Care
- Behavioral · Other
- Lead sponsor
- Baystate Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Actinic Keratosis, Photodynamic Therapy
- Interventions
- Celecoxib 200mg, Placebo
- Drug
- Lead sponsor
- Wright State University
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Fairborn, Ohio
- Conditions
- Congenital Diaphragmatic Hernia
- Interventions
- Congenital diaphragmatic hernia resuscitation with an intact umbilical cord
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 5 Minutes
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cystic Fibrosis
- Interventions
- VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 25
- States / cities
- New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
- Conditions
- Asymptomatic Bacteriuria
- Interventions
- sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
- Drug
- Lead sponsor
- NovaBay Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Not listed
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 27
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
- Conditions
- Healthy
- Interventions
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurocognitive Disorders, Neurodegenerative Diseases, Mental Disorders
- Interventions
- Tele-Savvy, Caregiving During Crisis (Educational Program)
- Behavioral
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Farmington, Connecticut • Atlanta, Georgia
- Conditions
- type1diabetes, Obesity
- Interventions
- Hyperinsulinemic-euglycemic clamp, High Fat Mixed Meal Tolerance Test
- Biological · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Volunteer
- Interventions
- GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Emotion Dysregulation
- Interventions
- Moms2B, DBT-P
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion, ATG
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- VV-14295
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Healthy Participants
- Interventions
- S-892216-LAI, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Cypress, California • Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Recurrent Head and Neck Cancer
- Interventions
- PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2, PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
- Combination Product
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more
- Conditions
- Small-cell Lung Cancer
- Interventions
- Berzosertib, Topotecan
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Topeka, Kansas • Bethesda, Maryland + 8 more
- Conditions
- Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
- Interventions
- NM1F Injection, Pembrolizumab injection
- Drug
- Lead sponsor
- Hefei TG ImmunoPharma Co., Ltd.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Fairfax, Virginia
- Conditions
- Osteoporosis, Postmenopausal, Bone Loss, Age-related
- Interventions
- Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High
- Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 45 Years to 70 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Intracranial Hemorrhage, Ventriculitis, Intracranial Abscess
- Interventions
- IRRAflow® CNS (Active Fluid Exchange) System
- Device
- Lead sponsor
- Christopher P Kellner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Large Tumor, Palliative Radiotherapy
- Interventions
- Lattice Radiation Therapy (LRT)
- Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
- Interventions
- Durvalumab, Oleclumab, FOLFOX, Bevacizumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sacramento, California • Ann Arbor, Michigan + 8 more